During the past decade, Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum" #1 collaborator was "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum" are "Invasive Ductal Breast Carcinoma" (1 trials), "Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)" (1 trials), "Metastatic Colorectal Cancer" (1 trials), "Nonsmall Cell Lung Cancer, Stage IV" (1 trials) and "Physical Activity" (1 trials). Many other conditions were trialed in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum" in a lesser frequency.

Most popular intervention types in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum" are "Drug" (3 trials), "Behavioral" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abraxane" (1 trials), "Anthra" (1 trials), "Carboplatin" (1 trials), "Counseling" (1 trials) and "FOLFIRI + Cetuximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum" are 2 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".